Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation
Clinical Lymphoma Myeloma and Leukemia · 2026
DOI: 10.1016/j.clml.2025.11.007 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Borja Puertas und 22 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de In…. Hauptthemen laut MEDLINE: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: The monoclonal gammopathy of uncertain significance (MGUS)-like model classifies multiple myeloma (MM) patients into 3 groups - MGUS-like, intermediate and MM-like--based on quantification of plasma cells (PCs) and clonal PCs in bone marrow, with distinct progression-free survival (PFS). We hypothesize that this model identifies patients with different characteristics that may influence the efficacy of autologous stem cell transplantation (ASCT). METHODS: A multicenter retrospective study was conducted including MM who underwent ASCT in the University Hospital of Salamanca between 2005 and 2023. The phenotypic profile was performed using the calculator available on the web site https://www.mgus-like.com/ RESULTS: Four hundred and fifteen patients who underwent ASCT between 2005 and 2023 were included: 39 MGUS-like (9.4%), 187 intermediate (45.1%) and 189 (45.5%) MM-like. MGUS-like patients more likely had low ISS/R-ISS, less BM infiltration, less secretory disease, less CRAB (except for lytic lesions) and had more bone-related plasmacytomas. Most patients received ASCT in the first line, with no differences in induction regimens among groups. The MGUS-like group achieved stronger responses after ASCT, defined as complete response and minimal residual disease negative (CR MRD-ve), 70.3%, than the intermediate (47.0%) and MM-like groups (40.6%). Additionally, the MGUS-like profile was identified as an independent predictor of CR MRD-ve and PFS, decreasing the likelihood of progression or death by 40% to 60% to the other phenotypic profiles. CONCLUSION: The MGUS-like profile is a baseline-evaluable feature that identifies a subset of patients with distinct clinical behavior and may predict greater benefit from high-dose melphalan, due to the high rate of CR MRD-ve resulting in longer survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology Department, University Hospital of Salamanca/ Instituto de Investigación Biomédica de Salamanca/Cancer Research Center IBMCC, Centro de Investigación Biomédica en Red del Cáncer, Salamanca, Spain.
- Hematology Department, University Hospital of Burgos, Burgos, Spain.
- Hematology Department, University Hospital of León, León, Spain.
- Hematology Department, Nuestra Señora de Sonsoles, Ávila, Spain.
- Hematology Department, University Hospital of Segovia, Segovia, Spain.
- Hematology Department, Hospital Río Carrión, Palencia, Spain.
Zitieren
APA
Puertas, B., Alejo, E., Pérez-Morán, J. J., Serra-Toral, F., Padilla, I., Dávila-Valls, J., García-Mateo, A., Alonso-Alonso, J. M., Hernández, R., Aguilar-Franco, C., López-López, R., García-Coca, A., Cantalapiedra-Diez, A., Bárez, A., Rey-Búa, B., López-Corral, L., Flores-Montero, J., Vidriales-Vicente, M. B., Gutiérrez, N. C., …, & Mateos, M. V. (2026). Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.11.007
Vancouver
Puertas B, Alejo E, Pérez-Morán JJ, Serra-Toral F, Padilla I, Dávila-Valls J, et al. Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2025.11.007
BibTeX
@article{Puertas2026,
author = {Puertas, Borja and Alejo, Elena and Pérez-Morán, José J and Serra-Toral, Fe and Padilla, Irene and Dávila-Valls, Julio and García-Mateo, Aránzazu and Alonso-Alonso, José María and Hernández, Roberto and Aguilar-Franco, Carlos and López-López, Rosa and García-Coca, Alfonso and Cantalapiedra-Diez, Alberto and Bárez, Abelardo and Rey-Búa, Beatriz and López-Corral, Lucía and Flores-Montero, Juan and Vidriales-Vicente, M Belén and Gutiérrez, Norma C and González-Calle, Verónica and Escalante, Fernando and Puig, Noemi and Mateos, Maria-Victoria},
title = {Clinic-Biological Features and Prognostic Significance of MGUS-Like Myeloma who underwent to Autologous Stem Cell Transplantation},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2025.11.007}
}
EUVIMED